Exploring disease-drug pairs in Clinical Trials information for personalized drug repurposing

Author:

Álvarez-Pérez AndreaORCID,Prieto-Santamaría LucíaORCID,Ugarte-Carro Esther,Otero-Carrasco BelénORCID,Ayuso-Muñoz AdriánORCID,Rodríguez-González AlejandroORCID

Abstract

AbstractDrug repurposing, the process of finding new uses for existing drugs, has gained considerable attention due to its potential to reduce the time and costs associated with drug development. Personalized drug repurposing, in which drugs are selected based on the characteristics of individual patients, is an emerging approach that holds promise for improving clinical outcomes. In this context, exploring disease-drug pairs in already conducted clinical trials can provide valuable insights to identify promising patient populations for further study that may lead to personalized drug repositioning. Our analysis aims to shed a light into clinical outcomes by selecting the most appropriate repurposed drug based on clinical trials patient groups’ characteristics, such as age and gender. It also gives information about the state of the clinical trials studying these disease-drug pairs, gathering information about the study type, phase and statistical method used to calculate the p-value of the chosen outcome measurement, among others. Overall, this study highlights the importance of using existing knowledge as an initial framework to facilitate further research, particularly in providing patient-specific information. Furthermore, it underlines the importance of building on previous research to facilitate a comprehensive understanding of the research topic, which can eventually improve patient outcomes.

Publisher

Cold Spring Harbor Laboratory

Reference14 articles.

1. Drug repositioning for personalized medicine

2. A data-driven methodology towards evaluating the potential of drug repurposing hypotheses

3. Impact of Precision Medicine on Drug Repositioning and Pricing: A Too Small to Thrive Crisis

4. Personalized medicine: motivation, challenges, and progress

5. M. T. Md , “A Phase II, Randomized, Double-blinded, Placebocontrolled Trial of Liraglutide in Parkinson’s Disease,” clinicaltrials.gov, Clinical trial registration NCT02953665 , Oct. 2022. Accessed: Jan. 30, 2023. [Online]. Available: https://clinicaltrials.gov/ct2/show/NCT02953665

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3